Phase 3 N=183 Superficial, Cervical Block in Thyroid Surgery, a Randomized Controlled Trial
Thyroidectomy
Primary: Post-operative Pain Measured by Visual Analogue Scale — 2.15; 2.02; 2.84; 2.72 units on a scale — p=.028
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=313 A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
Anemia
Primary: Mean Change in Hemoglobin Concentration (g/dL) From Baseline to Evaluation Period — 0.05; -0.10 gram per deciliter (g/dL) — p=< 0.0001
Phase 3 N=43 Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
Advanced Cancer
Primary: Functional Assessment of Cancer Therapy-Fatigue Subscale (FACIT-F) at Day 29 (+/- 3 Days) — 12; 13; 12; 14 units on a scale
Phase 3 N=138 Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain
Low Back Pain
Primary: Pain Intensity Difference (PID) From Pre-dose Baseline to 8h After the First Trial Medication Application (PID8h) — -0.98; -2.82 points on a scale — p=<0.0001
Phase 3 N=503 Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
Acne Vulgaris
Primary: Success Rate — 33.7; 27.3; 11.0; 31.9 percentage of participants
Phase 3 N=353 HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF)
Paroxysmal Atrial Fibrillation
Primary: Number of Participants That Meeting the Efficacy Success Criteria as Described in the Outcome Measure Description — 102; 103 Successful Participants
Phase 3 N=120 SONOlysis in Risk REduction of Symptomatic and Silent Brain infarCtions dUring Cardiac surgEry
Coronary Artery Bypass Graft Redo · Heart Valve Diseases
Primary: Number od Participants With New Brain Infarction in the Monitored MCA Territory Detected Using MRI — 8; 16; 52; 44 participants — p=<0.05
Phase 3 N=242 SONOlysis in Prevention of Brain Infarctions dUring Carotid Stenting and caroTid EndaRterectomy
Internal Carotid Artery Stenosis
Primary: Participants With a New Brain Infarction Detected Using Magnetic Resonance — 5; 15; 33; 42 participants
Phase 3 N=138 Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)
Hemophilia A
Primary: Annualized Bleeding Rate (ABR) — 4.3; 43.4 Bleeds per year — p=<0.0001
Phase 3 N=227 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
Eosinophilic Esophagitis
Primary: Mean Percent Change From Baseline to End of Treatment in Peak Esophageal Eosinophil (EE) Levels — -37.60; -58.27; -56.46; 11.50 percentage change in eosinophils/hpf…
Phase 3 N=23 BAX 326 Pediatric Study
Hemophilia B
Primary: Adverse Events (AEs) Possibly or Probably Related to BAX326 — 0; 0; 0 AEs considered related to BAX326
Phase 3 N=280 Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring
Sleep Apnea Syndromes
Primary: Nightly CPAP Adherence — 3.7; 3.7; 3.7; 3.2 hours per night — p=0.50
Phase 3 N=89 Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Primary Hyperlipidemia and Mixed Dyslipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR) — -5.07; 74.13; 83.70; 310.48 percent change — p=0.018
Phase 3 N=1,887 A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
Urologic Diseases · Urinary Bladder, Overactive · Urinary Bladder Diseases
Primary: Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours — -2.95; -3.13 micturitions — p=0.15
Phase 3 N=740 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Primary: Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6 — 79.1; 80.6 percentage of participants